Comparing the Nab-PHP and TCbHP in Neoadjuvant Therapy for Operable Breast Cancer With HER2 Positive, A Multicenter, Randomized, Phase III Clinical Trial
Condition: Breast Cancer,Her2 Positive Interventions: Drug: Albumin binding paclitaxel+ trastuzumab+ patuzumab; Drug: Docetaxel+ carboplatin+ trastuzumab + patuzumab Sponsor: Henan Cancer Hospital Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Breast Cancer | Cancer | Cancer & Oncology | Clinical Trials | Docetaxel | HER2 | Herceptin | Hospitals | Neoadjuvant Therapy | Research | Taxotere